智通财经网·2026-01-14 10:08Core Viewpoint - Fosun Pharma's subsidiary, Suzhou Er Ye Pharmaceutical, has recently had its drug registration application for injectable lactulose erythromycin accepted by the National Medical Products Administration of China [1] Group 1: Drug Information - The drug is a chemical medication intended for use when oral administration is not feasible or when a rapid high serum concentration of erythromycin is required to treat infections caused by specific sensitive microbial strains [1] - It is also indicated for the prevention of initial rheumatic fever, recurrence of rheumatic fever, and bacterial endocarditis [1] Group 2: Financials and Market Potential - As of December 2025, the cumulative R&D investment for this drug by the group is approximately RMB 6.33 million (unaudited) [1] - According to the latest data from IQVIA CHPA, the sales revenue of injectable lactulose erythromycin in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be around RMB 170 million in 2024 [1]